Bimodal Expansion of the Lymphatic Vessels Is Regulated by the Sequential Expression of IL-7 and Lymphotoxin α1β2 in Newly Formed Tertiary Lymphoid Structures

• Published in: The Journal of immunology (1950) Vol. 197; no. 5; pp. 1957 - 1967
• Main Authors: Nayar, Saba, Campos, Joana, Chung, Ming May, Navarro-Núñez, Leyre, Chachlani, Menka, Steinthal, Nathalie, Gardner, David H, Rankin, Philip, Cloake, Thomas, Caamaño, Jorge H, McGettrick, Helen M, Watson, Steve P, Luther, Sanjiv, Buckley, Christopher D, Barone, Francesca
• Format: Journal Article
• Language: English
• Published: United States AAI 01.09.2016
• Subjects: Animals; Gene Expression Regulation; Inflammation; Interleukin-7 - genetics; Interleukin-7 - immunology; Interleukin-7 - metabolism; Lymphangiogenesis; Lymphatic Vessels - immunology; Lymphatic Vessels - metabolism; Lymphotoxin alpha1, beta2 Heterotrimer - genetics; Lymphotoxin alpha1, beta2 Heterotrimer - immunology; Lymphotoxin alpha1, beta2 Heterotrimer - metabolism; Mice; Mucosal Immunology; Salivary Glands - immunology; Signal Transduction - genetics; Signal Transduction - immunology; Tertiary Lymphoid Structures - immunology; Tertiary Lymphoid Structures - pathology
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.1500686

Lymphangiogenesis associated with tertiary lymphoid structure (TLS) has been reported in numerous studies. However, the kinetics and dynamic changes occurring to the lymphatic vascular network during TLS development have not been studied. Using a viral-induced, resolving model of TLS formation in the salivary glands of adult mice we demonstrate that the expansion of the lymphatic vascular network is tightly regulated. Lymphatic vessel expansion occurs in two distinct phases. The first wave of expansion is dependent on IL-7. The second phase, responsible for leukocyte exit from the glands, is regulated by lymphotoxin (LT)βR signaling. These findings, while highlighting the tight regulation of the lymphatic response to inflammation, suggest that targeting the LTα1β2/LTβR pathway in TLS-associated pathologies might impair a natural proresolving mechanism for lymphocyte exit from the tissues and account for the failure of therapeutic strategies that target these molecules in diseases such as rheumatoid arthritis.